Dilemma of indication for thrombolysis in a patient with acute ischemic stroke treated with a novel oral anticoagulant

András Folyovich, Viktória Varga, Katalin A. Béres-Molnár, Károly Vadasdi, D. Bereczki

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Increasing age of the population is associated with a higher rate of cerebrovascular diseases, and every sixth stroke is the consequence of atrial fibrillation. In atrial fibrillation, vitamin K antagonists are routinely used to prevent cardioembolic strokes. Thrombolytic treatment recombinant tissue-type plasminogen activator (rt-PA) has established efficacy in acute ischemic stroke, but in anticoagulated patients, its use is contraindicated for those with an international normalized ratio of 1.7 or more. Recently, novel oral anticoagulants have become available. With conventional methods, however, it is difficult to assess the coagulation status of patients on these new treatments. We report the case of a patient treated with dabigatran who developed acute ischemic stroke and was considered for thrombolysis. Because of the prolonged thrombin time (TT), thrombolysis was not performed. Repeated coagulation tests 5 days after stroke, with unchanged anticoagulant (dabigatran) treatment, found 2-fold higher TT and activated partial thromboplastin time (APTT) compared with the values found in the acute stage. Routine coagulation tests (TT and APTT) do not reliably reflect the coagulation features of a patient; therefore, there is an urgent need to develop reliable biomarkers and an adequate guideline to help decision making regarding thrombolysis in those who develop their strokes while on one of these new oral anticoagulants.

Original languageEnglish
Pages (from-to)580-582
Number of pages3
JournalJournal of Stroke and Cerebrovascular Diseases
Volume23
Issue number3
DOIs
Publication statusPublished - 2014

Fingerprint

Anticoagulants
Stroke
Thrombin Time
Partial Thromboplastin Time
Atrial Fibrillation
Cerebrovascular Disorders
International Normalized Ratio
Vitamin K
Tissue Plasminogen Activator
Decision Making
Therapeutics
Biomarkers
Guidelines
Population
Dabigatran

Keywords

  • Acute ischemic stroke
  • cardiogenic embolism
  • novel oral anticoagulants
  • thrombolytic treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery
  • Rehabilitation
  • Cardiology and Cardiovascular Medicine

Cite this

Dilemma of indication for thrombolysis in a patient with acute ischemic stroke treated with a novel oral anticoagulant. / Folyovich, András; Varga, Viktória; Béres-Molnár, Katalin A.; Vadasdi, Károly; Bereczki, D.

In: Journal of Stroke and Cerebrovascular Diseases, Vol. 23, No. 3, 2014, p. 580-582.

Research output: Contribution to journalArticle

Folyovich, András ; Varga, Viktória ; Béres-Molnár, Katalin A. ; Vadasdi, Károly ; Bereczki, D. / Dilemma of indication for thrombolysis in a patient with acute ischemic stroke treated with a novel oral anticoagulant. In: Journal of Stroke and Cerebrovascular Diseases. 2014 ; Vol. 23, No. 3. pp. 580-582.
@article{fccb08f11d884d0b9fd023b5e1635f32,
title = "Dilemma of indication for thrombolysis in a patient with acute ischemic stroke treated with a novel oral anticoagulant",
abstract = "Increasing age of the population is associated with a higher rate of cerebrovascular diseases, and every sixth stroke is the consequence of atrial fibrillation. In atrial fibrillation, vitamin K antagonists are routinely used to prevent cardioembolic strokes. Thrombolytic treatment recombinant tissue-type plasminogen activator (rt-PA) has established efficacy in acute ischemic stroke, but in anticoagulated patients, its use is contraindicated for those with an international normalized ratio of 1.7 or more. Recently, novel oral anticoagulants have become available. With conventional methods, however, it is difficult to assess the coagulation status of patients on these new treatments. We report the case of a patient treated with dabigatran who developed acute ischemic stroke and was considered for thrombolysis. Because of the prolonged thrombin time (TT), thrombolysis was not performed. Repeated coagulation tests 5 days after stroke, with unchanged anticoagulant (dabigatran) treatment, found 2-fold higher TT and activated partial thromboplastin time (APTT) compared with the values found in the acute stage. Routine coagulation tests (TT and APTT) do not reliably reflect the coagulation features of a patient; therefore, there is an urgent need to develop reliable biomarkers and an adequate guideline to help decision making regarding thrombolysis in those who develop their strokes while on one of these new oral anticoagulants.",
keywords = "Acute ischemic stroke, cardiogenic embolism, novel oral anticoagulants, thrombolytic treatment",
author = "Andr{\'a}s Folyovich and Vikt{\'o}ria Varga and B{\'e}res-Moln{\'a}r, {Katalin A.} and K{\'a}roly Vadasdi and D. Bereczki",
year = "2014",
doi = "10.1016/j.jstrokecerebrovasdis.2013.04.029",
language = "English",
volume = "23",
pages = "580--582",
journal = "Journal of Stroke and Cerebrovascular Diseases",
issn = "1052-3057",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Dilemma of indication for thrombolysis in a patient with acute ischemic stroke treated with a novel oral anticoagulant

AU - Folyovich, András

AU - Varga, Viktória

AU - Béres-Molnár, Katalin A.

AU - Vadasdi, Károly

AU - Bereczki, D.

PY - 2014

Y1 - 2014

N2 - Increasing age of the population is associated with a higher rate of cerebrovascular diseases, and every sixth stroke is the consequence of atrial fibrillation. In atrial fibrillation, vitamin K antagonists are routinely used to prevent cardioembolic strokes. Thrombolytic treatment recombinant tissue-type plasminogen activator (rt-PA) has established efficacy in acute ischemic stroke, but in anticoagulated patients, its use is contraindicated for those with an international normalized ratio of 1.7 or more. Recently, novel oral anticoagulants have become available. With conventional methods, however, it is difficult to assess the coagulation status of patients on these new treatments. We report the case of a patient treated with dabigatran who developed acute ischemic stroke and was considered for thrombolysis. Because of the prolonged thrombin time (TT), thrombolysis was not performed. Repeated coagulation tests 5 days after stroke, with unchanged anticoagulant (dabigatran) treatment, found 2-fold higher TT and activated partial thromboplastin time (APTT) compared with the values found in the acute stage. Routine coagulation tests (TT and APTT) do not reliably reflect the coagulation features of a patient; therefore, there is an urgent need to develop reliable biomarkers and an adequate guideline to help decision making regarding thrombolysis in those who develop their strokes while on one of these new oral anticoagulants.

AB - Increasing age of the population is associated with a higher rate of cerebrovascular diseases, and every sixth stroke is the consequence of atrial fibrillation. In atrial fibrillation, vitamin K antagonists are routinely used to prevent cardioembolic strokes. Thrombolytic treatment recombinant tissue-type plasminogen activator (rt-PA) has established efficacy in acute ischemic stroke, but in anticoagulated patients, its use is contraindicated for those with an international normalized ratio of 1.7 or more. Recently, novel oral anticoagulants have become available. With conventional methods, however, it is difficult to assess the coagulation status of patients on these new treatments. We report the case of a patient treated with dabigatran who developed acute ischemic stroke and was considered for thrombolysis. Because of the prolonged thrombin time (TT), thrombolysis was not performed. Repeated coagulation tests 5 days after stroke, with unchanged anticoagulant (dabigatran) treatment, found 2-fold higher TT and activated partial thromboplastin time (APTT) compared with the values found in the acute stage. Routine coagulation tests (TT and APTT) do not reliably reflect the coagulation features of a patient; therefore, there is an urgent need to develop reliable biomarkers and an adequate guideline to help decision making regarding thrombolysis in those who develop their strokes while on one of these new oral anticoagulants.

KW - Acute ischemic stroke

KW - cardiogenic embolism

KW - novel oral anticoagulants

KW - thrombolytic treatment

UR - http://www.scopus.com/inward/record.url?scp=84896323323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896323323&partnerID=8YFLogxK

U2 - 10.1016/j.jstrokecerebrovasdis.2013.04.029

DO - 10.1016/j.jstrokecerebrovasdis.2013.04.029

M3 - Article

VL - 23

SP - 580

EP - 582

JO - Journal of Stroke and Cerebrovascular Diseases

JF - Journal of Stroke and Cerebrovascular Diseases

SN - 1052-3057

IS - 3

ER -